These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 8405226

  • 1. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD.
    Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
    [Abstract] [Full Text] [Related]

  • 2. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
    Okuda K, Golub TR, Gilliland DG, Griffin JD.
    Oncogene; 1996 Sep 19; 13(6):1147-52. PubMed ID: 8808688
    [Abstract] [Full Text] [Related]

  • 3. Comparative analysis of signaling pathways between mast cell growth factor (c-kit ligand) and granulocyte-macrophage colony-stimulating factor in a human factor-dependent myeloid cell line involves phosphorylation of Raf-1, GTPase-activating protein and mitogen-activated protein kinase.
    Miyazawa K, Hendrie PC, Mantel C, Wood K, Ashman LK, Broxmeyer HE.
    Exp Hematol; 1991 Dec 19; 19(11):1110-23. PubMed ID: 1721591
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
    Ahmed M, Dusanter-Fourt I, Bernard M, Mayeux P, Hawley RG, Bennardo T, Novault S, Bonnet ML, Gisselbrecht S, Varet B, Turhan AG.
    Oncogene; 1998 Jan 29; 16(4):489-96. PubMed ID: 9484838
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.
    Oncogene; 2002 Nov 21; 21(53):8075-88. PubMed ID: 12444544
    [Abstract] [Full Text] [Related]

  • 8. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.
    Perrotti D, Bonatti S, Trotta R, Martinez R, Skorski T, Salomoni P, Grassilli E, Lozzo RV, Cooper DR, Calabretta B.
    EMBO J; 1998 Aug 03; 17(15):4442-55. PubMed ID: 9687511
    [Abstract] [Full Text] [Related]

  • 9. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW, Ren R.
    Oncogene; 2000 Dec 14; 19(54):6286-96. PubMed ID: 11175343
    [Abstract] [Full Text] [Related]

  • 10. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line.
    Laneuville P, Heisterkamp N, Groffen J.
    Oncogene; 1991 Feb 14; 6(2):275-82. PubMed ID: 1705688
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
    Chai SK, Nichols GL, Rothman P.
    J Immunol; 1997 Nov 15; 159(10):4720-8. PubMed ID: 9366395
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation.
    Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB.
    Cancer Res; 1996 Aug 01; 56(15):3426-30. PubMed ID: 8758906
    [Abstract] [Full Text] [Related]

  • 19. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
    Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M.
    Cancer Res; 1996 Aug 01; 56(15):3589-96. PubMed ID: 8758931
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.